Cellivery Therapeutics, Inc. announced a private placement of series 3 unregistered nonguaranteed private convertible bonds for a gross proceeds of KRW 19,500,000,000 and 387,668 shares at an issue price of KRW 50,300 per share for gross proceeds of KRW 19,499,700,400 for aggregate gross proceeds of KRW 38,999,700,400 on September 30, 2021. The company raised funding through third party allocation method. The transaction has been approved by the board of directors of the company.